Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.

Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.

This CME-accredited podcast explores the rationale for targeting human epidermal growth factor receptor 3 (HER3) in non–small cell lung cancer (NSCLC) and breast cancer. It includes an in-depth discussion of the mechanism of action, safety, and efficacy of agents that are being investigated to target HER3. The latest results from clinical trials investigating monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates targeting HER3 will also be discussed.

Heart failure contributes to more than 3 million hospital admissions, resulting in a considerable economic burden. Despite significant developments to advance treatment, hospital readmission rates also remain high. Join Drs. Javed Butler and John Boehmer as they discuss fluid overload in patients with heart failure and explore recent clinical evidence in remote monitoring strategies to improve patient outcomes.

Recently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This six-part series features distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.

This first activity focuses on the rise of amyloid-targeting DMT and the subsequent key features of ARIA that impact all specialties.

This program will focus on the clinical trial and real-world data about the novel and emerging therapies for the treatment of dry age-related macular degeneration, wet age-related macular degeneration, diabetic retinopathy, and diabetic macular edema and how these therapies may be integrated into real-world clinical practice.

Effective triage tests are needed to lessen diagnostic uncertainty when assessing cervical cancer risk and selecting which patients will move on to colposcopy. An FDA-approved dual-staining cytology test is available that can help in decision-making for a wide range of patients. Join Drs. Warner Huh and Sarah Dilley as they address current 2019 ASCCP guidelines and anticipate potential updates to ASCCP’s guidance in 2023.

This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

This series of bite-sized episodes contains important information you need to know about iron deficiency and iron deficiency anemia in your female patients. Dr. Malcolm Munro and colleagues discuss recent evidence and provide practical approaches for screening, diagnosing, treating, and preventing the progression of this condition.

Renowned international expert Dr. Roberto Romero joins Dr. Lee Shulman to walk us through maternal anti-fetal rejection. Find out about its pathophysiology, mechanisms of disease, approach to diagnosis, and potential treatment so that you can broaden your understanding and improve the care you provide.